4.6 Article

Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction

期刊

ATHEROSCLEROSIS
卷 211, 期 1, 页码 333-336

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2010.02.024

关键词

TRAIL; MMP2; TIMP2; Acute myocardial infarction

资金

  1. Programma di Ricerca Regione-Universita (Regione Emilia Romagna)

向作者/读者索取更多资源

Background: This study was designed to evaluate the potential role of metalloproteinase 2 (MMP2) in promoting the cleavage of TNF-related apoptosis inducing ligand (TRAIL), whose circulating levels are decreased after acute myocardial infarction (AMI). Methods: The levels of MMP2 and of tissue inhibitor of metalloprotease 2 (TIMP2), as well as of TRAIL, were measured by ELISA in the serum of AMI patients and in the culture supernatant of endothelial cells. Results: In AMI patients the serum levels of TRAIL showed a significant inverse correlation with the MMP2/TIMP2 ratio. In vitro MMP2 induced the cleavage of recombinant TRAIL and inactivated its ability of inducing apoptosis. Moreover, exposure of endothelial cells to TNF-alpha increased the MMP2/TIMP2 ratio in the culture supernatant. Conclusions: An impaired MMP2/TIMP2 ratio might be involved in the decreased levels of circulating TRAIL observed after AMI. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

Mitja Lainscak, Ivan Milinkovic, Marija Polovina, Marisa G. Crespo-Leiro, Lars H. Lund, Stefan D. Anker, Cecile Laroche, Roberto Ferrari, Andrew J. S. Coats, Theresa McDonagh, Gerasimos Filippatos, Aldo R. Maggioni, Massimo F. Piepoli, Giuseppe M. C. Rosano, Frank Ruschitzka, Dragan Simic, Milika Asanin, Jean-Christophe Eicher, Mehmet B. Yilmaz, Petar M. Seferovic

EUROPEAN JOURNAL OF HEART FAILURE (2020)

Review Biochemistry & Molecular Biology

Sex/Gender-Specific Imbalance in CVD: Could Physical Activity Help to Improve Clinical Outcome Targeting CVD Molecular Mechanisms in Women?

Mauro Vaccarezza, Veronica Papa, Daniela Milani, Arianna Gonelli, Paola Secchiero, Giorgio Zauli, Donato Gemmati, Veronica Tisato

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Letter Cardiac & Cardiovascular Systems

Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

Patrick Rossignol, Mitja Lainscak, Maria G. Crespo-Leiro, Cecile Laroche, Massimo F. Piepoli, Gerasimos Filippatos, Giuseppe M. C. Rosano, Gianluigi Savarese, Stefan D. Anker, Petar M. Seferovic, Frank Ruschitzka, Andrew J. S. Coats, Alexandre Mebazaa, Theresa McDonagh, Ana Sahuquillo, Maria Penco, Aldo P. Maggioni, Lars H. Lund

EUROPEAN JOURNAL OF HEART FAILURE (2020)

Article Cardiac & Cardiovascular Systems

Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

Chris J. Kapelios, Cecile Laroche, Maria G. Crespo-Leiro, Stefan D. Anker, Andrew J. S. Coats, Beatria Diaz-Molina, Gerasimos Filippatos, Mitja Lainscak, Aldo P. Maggioni, Theresa McDonagh, Alexandre Mebazaa, Marco Metra, Brenda Moura, Wilfried Mullens, Massimo F. Piepoli, Giuseppe M. C. Rosano, Frank Ruschitzka, Petar M. Seferovic, Lars H. Lund

EUROPEAN JOURNAL OF HEART FAILURE (2020)

Article Biochemistry & Molecular Biology

COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification

Francesco Vieceli Dalla Sega, Francesca Fortini, Paolo Cimaglia, Luisa Marracino, Elisabetta Tonet, Antonio Antonucci, Marco Moscarelli, Gianluca Campo, Paola Rizzo, Roberto Ferrari

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Cardiac & Cardiovascular Systems

Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Maria Lukacs Krogager, Kristian Kragholm, Jesper Qvist Thomassen, Peter Sogaard, Basil S. Lewis, Sven Wassmann, Iris Baumgartner, Claudio Ceconi, Thomas Andersen Schmidt, Juan Carlos Kaski, Heinz Drexel, Anne Grete Semb, Stefan Agewall, Alexander Niessner, Gianluigi Savarese, Keld Per Kjeldsen, Claudio Borghi, Juan Tamargo, Christian Torp-Pedersen

Summary: This review highlights the importance of tight potassium regulation in patients with cardiovascular disease, explaining the mechanisms of potassium homeostasis maintenance, common causes of hypokalaemia, and strategies for management. It suggests raising potassium levels in asymptomatic patients with lower normal concentrations and concurrent cardiovascular disease, providing assistance to clinicians in the absence of more evidence.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)

Article Medicine, General & Internal

The Combination of Chest Computed Tomography and Standard Electrocardiogram Provides Prognostic Information and Pathophysiological Insights in COVID-19 Pneumonia

Matteo Bertini, Emanuele D'Aniello, Alberto Cereda, Marco Toselli, Filippo Maria Verardi, Luca Rossi, Daniela Aschieri, Alberto Monello, Marco Manfrini, Davide Vignale, Anna Palmisano, Antonio Esposito, Roberto Ferrari, Claudio Rapezzi, Francesco Giannini

Summary: The study discovered that combining chest CT scan and ECG data can improve risk stratification in COVID-19 pneumonia by identifying a distinctive phenotype with both parenchymal and vascular damage of the lung. Patients with severe pneumonia at chest CT scan plus ECG signs of acute RV strain have an extremely poor short-term prognosis.

JOURNAL OF CLINICAL MEDICINE (2021)

Review Medicine, General & Internal

Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?

Alessandro Fucili, Paolo Cimaglia, Paolo Severi, Francesco Giannini, Alberto Boccadoro, Marco Micillo, Claudio Rapezzi, Luigi Tavazzi, Roberto Ferrari

Summary: After a decade of stagnation in clinical research for HF treatment, five large randomized trials have recently supported the use of four new classes of drugs, which have proven beneficial for long-term outcomes and quality of life. Beyond their clinical relevance, these novel treatments have different mechanisms of action compared to traditional neuro-hormonal blocking agents. The diverse pathways and solid clinical evidence urge a re-evaluation of HF treatment and personalized drug selection based on patient characteristics.

JOURNAL OF CLINICAL MEDICINE (2021)

Review Biochemistry & Molecular Biology

Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape

Francesca Fortini, Francesco Vieceli Dalla Sega, Luisa Marracino, Paolo Severi, Claudio Rapezzi, Paola Rizzo, Roberto Ferrari

Summary: Endothelial dysfunction is a central feature of the cardiovascular continuum, influencing the prognosis and treatment outcomes of cardiovascular diseases. COVID-19-related endothelial dysfunction leads to severe complications, particularly in high-risk individuals with existing endothelial dysfunction.

BIOMEDICINES (2021)

Article Chemistry, Medicinal

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib

Annalisa Marcuzzi, Erika Rimondi, Elisabetta Melloni, Arianna Gonelli, Antonio Giacomo Grasso, Egidio Barbi, Natalia Maximova

Summary: Janus kinases (JAKs), as a family of tyrosine kinases, play important roles in immune cell regulation by transducing cytokine-mediated signals through the JAK-STAT pathway. In recent years, JAK inhibitors have shown promise in the treatment of various inflammatory conditions, including acute steroid-refractory graft-versus-host disease (SR-aGVHD). Ruxolitinib, a JAK1/2 inhibitor, has been approved by the FDA for the treatment of SR-aGVHD and has demonstrated rapid and effective response.

PHARMACEUTICALS (2022)

Article Biology

Cardiac Calcifications: Phenotypes, Mechanisms, Clinical and Prognostic Implications

Francesco Vieceli Dalla Sega, Francesca Fortini, Paolo Severi, Paola Rizzo, Iija Gardi, Paolo Cimaglia, Claudio Rapezzi, Luigi Tavazzi, Roberto Ferrari

Summary: This review discusses the pathogenesis and therapeutic approaches of vascular and heart calcifications in different conditions. Calcifications are complex disorders that have significant implications for cardiovascular and kidney diseases.

BIOLOGY-BASEL (2022)

Article Cardiac & Cardiovascular Systems

Sex differences in arterial hypertension A scientific statement from the ESC Council on Hypertension, the European Association of Preventive Cardiology, Association of Cardiovascular Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the ESC Working Group on Cardiovascular Pharmacotherapy

Eva Gerdts, Isabella Sudano, Sofie Brouwers, Claudio Borghi, Rosa Maria Bruno, Claudio Ceconi, Veronique Cornelissen, Francois Dievart, Marc Ferrini, Thomas Kahan, Maja Lisa Lochen, Angela H. E. M. Maas, Felix Mahfoud, Anastasia S. Mihailidou, Trine Moholdt, Gianfranco Parati, Giovanni de Simone

Summary: Sex chromosomes and sex hormones play differential roles in blood pressure regulation and cardiovascular risk factors between females and males with essential arterial hypertension. The risk for cardiovascular disease is higher in females at lower blood pressure levels, suggesting the need for sex-specific thresholds in hypertension diagnosis. It is currently unknown if hypertension should be managed differently in females and males, highlighting the need for focused research on sex-specific prevention and management.

EUROPEAN HEART JOURNAL (2022)

Review Biochemistry & Molecular Biology

Mitochondria-Targeted Antioxidants, an Innovative Class of Antioxidant Compounds for Neurodegenerative Diseases: Perspectives and Limitations

Matteo Fields, Annalisa Marcuzzi, Arianna Gonelli, Claudio Celeghini, Natalia Maximova, Erika Rimondi

Summary: Neurodegenerative diseases are characterized by progressive loss of neuronal functions and structures. Mitochondrial dysfunction and oxidative stress have been identified as common mechanisms leading to neurodegeneration. Antioxidant therapies, specifically targeting mitochondria, have become increasingly important in reverting neuronal damage. Novel mitochondria-targeted antioxidant compounds, such as MitoQ, SkQ1, MitoVitE and MitoTEMPO, have been developed and studied to address the need for effective treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Meeting Abstract Oncology

External validation of the Hemo-Eosinophils-Inflammation index as a prognosticator in anal cancer

P. Franco, A. Porreca, M. Di Nicola, G. Mantello, F. Valvo, N. Slim, S. Manfrida, M. A. Gambacorta, F. De Felice, S. Vagge, M. Krengli, E. Palazzari, M. F. Osti, A. Gonelli, G. Catalano, P. Pittoni, M. Lupattelli, M. R. Niespolo, M. E. Rosetto, G. Macchia, O. Durante, F. Munoz, R. M. D'Angelillo, D. Genovesi, L. Caravatta

RADIOTHERAPY AND ONCOLOGY (2022)

Article Immunology

The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus

Alessandra Bortoluzzi, Cecilia Beatrice Chighizola, Micaela Fredi, Elena Raschi, Caterina Bodio, Daniela Privitera, Arianna Gonelli, Ettore Silvagni, Marcello Govoni, Ilaria Cavazzana, Paolo Airo, Pier Luigi Meroni, Angela Tincani, Franco Franceschini, Silvia Piantoni, Fabio Casciano

FRONTIERS IN IMMUNOLOGY (2020)

暂无数据